Provided by Tiger Trade Technology Pte. Ltd.

Pulmatrix

4.08
-0.1900-4.45%
Post-market: 4.07-0.0100-0.25%16:00 EST
Volume:19.11K
Turnover:78.30K
Market Cap:14.90M
PE:-2.39
High:4.28
Open:4.28
Low:3.90
Close:4.27
52wk High:10.40
52wk Low:3.90
Shares:3.65M
Float Shares:3.63M
Volume Ratio:2.75
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7073
EPS(LYR):-2.6173
ROE:-79.47%
ROA:-47.09%
PB:3.15
PE(LYR):-1.56

Loading ...

Pulmatrix Reports Q3 2025 Results and Strategic Shift

TIPRANKS
·
Oct 17

Pulmatrix reports Q3 EPS (24c) vs. (71c) last year

TIPRANKS
·
Oct 16

Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment

Reuters
·
Oct 16

Pulmatrix Q3 EPS $(0.24) Up From $(0.71) YoY

Benzinga
·
Oct 16

BRIEF-Pulmatrix Q3 EPS USD -0.24

Reuters
·
Oct 16

Pulmatrix Shareholders Approve Merger with Cullgen; Company Moves to Divest iSPERSE™ Technology and Migraine Assets

Reuters
·
Oct 16

Pulmatrix Q3 Operating Expenses USD 866 Thousand

THOMSON REUTERS
·
Oct 16

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

THOMSON REUTERS
·
Oct 16

Pulmatrix Q2 EPS $(0.42) Up From $(1.59) YoY

Benzinga
·
Aug 06

Pulmatrix Inc. Reports Q2 2025 Results: Revenues Drop to $0 from $1.6M, R&D Expenses Plummet by $2.8M

Reuters
·
Aug 06

Pulmatrix Inc. Advances Merger with Cullgen, Plans to Divest Inhalation Assets in 2025

Reuters
·
Aug 06

Pulmatrix Inc - Seeks Divestment of Isperse Patent Portfolio

THOMSON REUTERS
·
Aug 06

Pulmatrix Inc: to Also Potentially Divest Three Isperse Technology Related Clinical Programs

THOMSON REUTERS
·
Aug 06

Pulmatrix Q2 Operating Expenses USD 1.548 Million

THOMSON REUTERS
·
Aug 06

Pulmatrix Inc - Proposed Merger With Cullgen Anticipated to Close in 2025

THOMSON REUTERS
·
Aug 06

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

THOMSON REUTERS
·
Aug 06

Pulmatrix Inc. Conducted Special Stockholders Meeting on Merger Proposals

Reuters
·
Jun 17